Utilizing the Stanford Integrated Psychosocial Assessment for Transplant (SIPAT) Measure to Predict Left Ventricular Assist Device (LVAD) Outcomes

Purpose Approximately 5.7 million adults in the United States are diagnosed with heart failure (HF). Durable mechanical circulatory support (MCS) is a proven therapy to improve survival for those who progress to stage IV HF and have failed guideline directed medical therapy (GDMT). When selecting candidates for durable MCS, ISHLT guidelines recommend a detailed psychosocial assessment including: treatment adherence/health behaviors, mental health history, substance use history, cognitive status and capacity to give consent, knowledge and understanding of illness and treatment options, coping with illness, social support, social history, knowledge about and capacity to operate MCS devices. Currently, there are no formally validated psychosocial evaluation tools for LVAD candidacy; though they are commonly used for heart transplant evaluation. The Stanford Integrated Psychosocial Assessment for Transplantation (SIPAT) uses a multidisciplinary algorithm to evaluate the impact of pre-transplant risk factors on post-transplant outcomes. Emerging literature suggests that the SIPAT might be useful for assessing psychosocial risk factors for LVAD intervention; though further research is needed. Methods This study examined the association of SIPAT scores for patients undergoing evaluation for durable MCS with 30-day readmission, 30-day mortality, two-year readmission and two-year mortality rates. Two hundred and sixty-eight (268) consecutive patients (median age 66 years, 15.4% female) with terminal HF were evaluated prior to LVAD implantation with a SIPAT assessment. Two hundred and thirty-four (234) of those patients had available 30-day and 2-year outcome data. Results Results indicated a significant relationship between total scores on the SIPAT and two-year mortality rates (r= .251, n= 234, p Conclusion Consistent with transplant outcomes, higher SIPAT scores were associated with poorer outcomes, specifically mortality, in LVAD patients.